Menu
31/05/2017
Researchers Make 'Breakthrough Discovery' In Bowel Cancer Treatment
Researchers at Queen's University in Belfast have made a "breakthrough discovery" in the treatment of bowel cancer.
New research has found how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.
For clinicians, treating patients with bowel cancer can be particularly challenging. Professor Mark Lawler, Chair in Translational Genomics, Centre for Cancer Research and Cell Biology at Queen's and joint Senior Author on the study said: "Currently patients with colorectal cancer are offered chemotherapy treatment. While this treatment may be successful for some patients, for others it will have no effect on fighting the cancer, though the patients may suffer debilitating side effects such as nerve damage that can result in a loss of sensation or movement in a part of the body. A ‘one size fits all’ approach isn't a viable option if we are to effectively tackle this disease."
Researchers at Queen's, in collaboration with the University of Oxford and the University of Leeds have made a significant advance in the treatment of bowel cancer. The study, which has been published in the high impact journal Nature Communications, has shown how defining precise gene signatures within bowel cancer cells can allow us to develop novel prognostic and predictive markers for bowel cancer and help to drive personalised medicine approaches.
Dr Philip Dunne, Senior Research Fellow at Queen’s said: "Through analysing the molecular and genetic data generated from patient tissue samples, we have discovered that there are different subtypes of bowel cancer. This research unequivocally identifies robust gene signatures that can be used to inform patient management.
"It will allow us to identify particular gene signatures that indicate sensitivity or resistance to specific therapies. Thus, we can tailor treatment to the individual patient, maximising its effectiveness while minimising potential side effects."
The research was performed as part of Stratified Medicine in Colorectal Cancer (S:CORT), an MRC-Cancer Research UK funded stratified medicine consortium, bringing together the best of UK science and clinical care in bowel cancer to develop personalised medicine treatment approaches in this common malignancy.
New research has found how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.
For clinicians, treating patients with bowel cancer can be particularly challenging. Professor Mark Lawler, Chair in Translational Genomics, Centre for Cancer Research and Cell Biology at Queen's and joint Senior Author on the study said: "Currently patients with colorectal cancer are offered chemotherapy treatment. While this treatment may be successful for some patients, for others it will have no effect on fighting the cancer, though the patients may suffer debilitating side effects such as nerve damage that can result in a loss of sensation or movement in a part of the body. A ‘one size fits all’ approach isn't a viable option if we are to effectively tackle this disease."
Researchers at Queen's, in collaboration with the University of Oxford and the University of Leeds have made a significant advance in the treatment of bowel cancer. The study, which has been published in the high impact journal Nature Communications, has shown how defining precise gene signatures within bowel cancer cells can allow us to develop novel prognostic and predictive markers for bowel cancer and help to drive personalised medicine approaches.
Dr Philip Dunne, Senior Research Fellow at Queen’s said: "Through analysing the molecular and genetic data generated from patient tissue samples, we have discovered that there are different subtypes of bowel cancer. This research unequivocally identifies robust gene signatures that can be used to inform patient management.
"It will allow us to identify particular gene signatures that indicate sensitivity or resistance to specific therapies. Thus, we can tailor treatment to the individual patient, maximising its effectiveness while minimising potential side effects."
The research was performed as part of Stratified Medicine in Colorectal Cancer (S:CORT), an MRC-Cancer Research UK funded stratified medicine consortium, bringing together the best of UK science and clinical care in bowel cancer to develop personalised medicine treatment approaches in this common malignancy.
Related Northern Ireland News Stories
Click here for the latest headlines.
27 April 2012
Durkan Pledges To Help Save Lives From Bowel Cancer
SDLP Foyle MP Mark Durkan has pledged his support to help save lives from bowel cancer this week at Westminster after attending a parliamentary reception to mark the 25th Anniversary of Bowel Cancer UK and the launch of the charity's new report 2025 Challenge: Saving and Improving Lives.
Durkan Pledges To Help Save Lives From Bowel Cancer
SDLP Foyle MP Mark Durkan has pledged his support to help save lives from bowel cancer this week at Westminster after attending a parliamentary reception to mark the 25th Anniversary of Bowel Cancer UK and the launch of the charity's new report 2025 Challenge: Saving and Improving Lives.
04 April 2024
Public Health Agency Issues Bowel Cancer Awareness Info
The Public Health Agency (PHA) has urged people to be aware of the risks of bowel cancer and the two key actions – act when you notice symptoms, and take part in screening if eligible.
Public Health Agency Issues Bowel Cancer Awareness Info
The Public Health Agency (PHA) has urged people to be aware of the risks of bowel cancer and the two key actions – act when you notice symptoms, and take part in screening if eligible.
18 July 2014
QUB Bowel Cancer 'Breakthrough'
Researchers at Queen’s University say they have made "a significant breakthrough" that could benefit patients with bowel cancer. Study author Dr Sandra van Schaeybroeck and her team have discovered how genes cause bowel cancer cells to become resistant to treatment.
QUB Bowel Cancer 'Breakthrough'
Researchers at Queen’s University say they have made "a significant breakthrough" that could benefit patients with bowel cancer. Study author Dr Sandra van Schaeybroeck and her team have discovered how genes cause bowel cancer cells to become resistant to treatment.
03 February 2012
Extended Bowel Screening Programme Welcomed
The Ulster Cancer Foundation (UCF) has welcomed news that Northern Ireland's bowel cancer screening programme is to be extended with more people being targeted across all of the health trusts.
Extended Bowel Screening Programme Welcomed
The Ulster Cancer Foundation (UCF) has welcomed news that Northern Ireland's bowel cancer screening programme is to be extended with more people being targeted across all of the health trusts.
24 April 2023
Symptom Awareness Key To Tackling Bowel Cancer
With about one in 20 people developing bowel cancer in their lifetime, the Public Health Agency (PHA) has highlighted how being alert to the possible symptoms and taking part in screening could help save your life.
Symptom Awareness Key To Tackling Bowel Cancer
With about one in 20 people developing bowel cancer in their lifetime, the Public Health Agency (PHA) has highlighted how being alert to the possible symptoms and taking part in screening could help save your life.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
